表紙
市場調查報告書
商品編碼
1028953

全球Adalimumab,Infliximab,Etanercept的生物相似藥市場報告:2021年版 - COVID-19擴大和到2030年前的變化

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

出版日期: 按訂單生產 | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球Adalimumab,Infliximab,Etanercept的生物相似藥市場相關調查,網羅市場特性,規模與成長,市場區隔,各地各國趨勢,競爭情形,市場佔有率,市場趨勢與策略。還有各地區的市場的實際成果與預測,及加入此市場的主要企業的簡介等資訊。

目錄

第1章 摘要整理

第2章 Adalimumab,Infliximab,Etanercept的生物相似藥市場特徵

第3章 Adalimumab,Infliximab,Etanercept的生物相似藥市場趨勢與策略

第4章 COVID-19對Adalimumab,Infliximab,Etanercept的生物相似藥的影響

第5章 Adalimumab,Infliximab,Etanercept的生物相似藥的市場規模與成長

  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場實際成果,2015∼2020年,10億美元
    • 市場促進因素
    • 市場阻礙因素
  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場預測,2020∼2025年,2030年,10億美元
    • 市場促進因素
    • 市場阻礙因素

第6章 Adalimumab,Infliximab,Etanercept的生物相似藥市場細分化

  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • Adalimumab的生物相似藥(Exemptia,Mabura,Hyrimoz,Hadlima,Abrilada,其他)
  • Infliximab的生物相似藥(Inflectra,Renflexis,Ixifi,Avsola)
  • Cipleumab(Erelzi,Eticovo)
  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場,各用途市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • 克隆氏症
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 潰瘍性大腸炎
  • 僵直性脊椎炎
  • 斑塊型乾癬
  • 其他
  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場,各流通管道的市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • 院內藥局
  • 零售藥局
  • 線上藥局

第7章 Adalimumab,Infliximab,Etanercept的生物相似藥市場各地區以及各國分析

  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場,各地區,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • 全球Adalimumab,Infliximab,Etanercept的生物相似藥市場,各國,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第8章 亞太地區的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 亞太地區的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 地區資訊,COVID-19的影響,市場資訊,背景資訊,政府的積極推動,法規,法規機關,主要的協會,免稅,公司稅結構,投資,主要企業
  • 亞太地區的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第9章 中國的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 中國的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 中國的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第10章 印度的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 印度的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第11章 日本的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 日本的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第12章 澳洲的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 澳洲的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第13章 印尼的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 印尼的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第14章 韓國的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 韓國的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第15章 西歐的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 西歐的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 西歐的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第16章 英國的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 英國的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第17章 德國的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 德國的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第18章 法國的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 法國的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第19章 東歐的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 東歐的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 東歐的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第20章 俄羅斯的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 俄羅斯的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第21章 北美的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 北美的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 北美的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第22章 美國的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 美國的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 美國的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第23章 南美的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 南美的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 南美的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第24章 巴西的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 巴西的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第25章 中東的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 中東的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 中東的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第26章 非洲的Adalimumab,Infliximab,Etanercept的生物相似藥市場

  • 非洲的Adalimumab,Infliximab,Etanercept的生物相似藥市場概要
  • 非洲的Adalimumab,Infliximab,Etanercept的生物相似藥市場,各產品市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第27章 Adalimumab,Infliximab,Etanercept的生物相似藥市場競爭情形和企業簡介

  • Adalimumab,Infliximab,Etanercept的生物相似藥市場競爭情形環境
  • Adalimumab,Infliximab,Etanercept的生物相似藥市場企業簡介
    • Zydus Cadila
    • Sandoz(Novartis)
    • Samsung Bioepis
    • Abbvie
    • Amgen

第28章 Adalimumab,Infliximab,Etanercept的生物相似藥開發平台分析

第29章 Adalimumab,Infliximab,Etanercept的生物相似藥市場上主要合併和收購

第30章 Adalimumab,Infliximab,Etanercept的生物相似藥市場未來展望和潛在性分析

第31章 附錄

目錄
Product Code: h978

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change to 2030 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global adalimumab, infliximab and etanercept biosimilars market.

This report focuses on adalimumab, infliximab and etanercept biosimilars market which is experiencing strong growth. The report gives a guide to the adalimumab, infliximab and etanercept biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Adalimumab, Infliximab and Etanercept Biosimilars market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider adalimumab, infliximab and etanercept biosimilars market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The adalimumab, infliximab and etanercept biosimilars market section of the report gives context. It compares the adalimumab, infliximab and etanercept biosimilars market with other segments of the adalimumab, infliximab and etanercept biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, adalimumab, infliximab and etanercept biosimilars indicators comparison.

Scope

Markets Covered:

1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)

2) By Application: Crohn'S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Others

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary

2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics

3. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies

4. Impact Of COVID-19 On Adalimumab, Infliximab and Etanercept Biosimilars

5. Adalimumab, Infliximab and Etanercept Biosimilars Market Size And Growth

  • 5.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Historic Market, 2015-2020, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Forecast Market, 2020-2025F, 2030F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

  • 6.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others)
  • Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola)
  • Cipleumab (Erelzi, Eticovo)
  • 6.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Crohn's disease
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis
  • Ankylosing spondylitis
  • Plaque psoriasis
  • Others
  • 6.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Adalimumab, Infliximab and Etanercept Biosimilars Market Regional And Country Analysis

  • 7.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • 7.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 8.1. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 9.1. China Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 9.2. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 10.1. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 11.1. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 12.1. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 13.1. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 14.1. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 15.1. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 15.2. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 16.1. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 17.1. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 18.3. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 19.1. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 19.2. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 20.1. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 21.1. North America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 21.2. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 22.1. USA Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 22.2. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 23.1. South America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 23.2. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 24.1. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 25.1. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 25.2. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 26.1. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 26.2. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape And Company Profiles

  • 27.1. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape
  • 27.2. Adalimumab, Infliximab and Etanercept Biosimilars Market Company Profiles
    • 27.2.1. Zydus Cadila
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Sandoz (Novartis)
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Samsung Bioepis
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Abbvie
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Amgen
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Adalimumab, Infliximab and Etanercept Biosimilars Pipeline Analysis

29. Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market

30. Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Research Inquiries
  • 31.4. The Business Research Company
  • 31.5. Copyright And Disclaimer